2015 American Transplant Congress
Basiliximab Induction With Delayed Tacrolimus Initiation up to 14 Days Post Liver Transplantation Maintains Excellent Clinical Outcomes While Preserving Renal Function
University of Virginia Health System, Charlottesville, VA.
Background: Calcineurin inhibitors are frequently delayed to allow for recovery of renal function after transplantation; however, there is a paucity of literature supporting a delay…2015 American Transplant Congress
Hepatic T Cells Derived from Normothemic Machine Perfused Grafts Contained More Regulatory T Cells and Fewer Proinflammatory Cytokines Producing T Cells Than Those from Cold Storage Grafts
Background & aim:In liver transplantation, ischemia reperfusion (I/R) injury is associated with an inflammatory response affecting graft and patient outcomes. Ex-vivo normothermic machine perfusion (NMP)…2015 American Transplant Congress
Clinical Utility of Allospecific CD154+T-Cells in Children With Liver Or Intestine Transplantation (LTx, ITx)
Background: Allospecific CD154+T-cytotoxic memory (CD154+TcM) have completed investigational evaluation as predictors of acute cellular rejection in children with LTx or ITx.Purpose: To evaluate CD154+TcM** as…2015 American Transplant Congress
Pharmacist-Led Renal-Sparing Conversion to Everolimus After Liver Transplantation
1Barnes-Jewish Hospital, St. Louis, MO; 2Washington University in St. Louis, St. Louis, MO.
Purpose: Preservation of renal function following orthotopic liver transplantation (OLT) through calcineurin inhibitor (CNI)-minimization is an established clinical objective. The use of everolimus (EVR) to…2015 American Transplant Congress
Everolimus-Based Immunosuppression Is Associated With a Reduced Risk of New-Onset Malignancies After Liver Transplantation
Background and aim: The inhibitor of the mammalian target of rapamycin (mTOR) everolimus (EVR) has shown anti-proliferative effects in experimental and clinical models. We investigated…2015 American Transplant Congress
Plasmapharesis, Intravenous Immunoglobulin and Rituximab Successfully Treat Recurrent Progressive Familial Intrahepatic Cholestasis Type 2 (PFIC-2) After Liver Transplantation
Background:Allo-immune mediated BSEP dysfunction may occur after liver transplantation in PFIC2 patients leading to a PFIC2 like phenotype. The IgG antibodies are reactive toward a…2015 American Transplant Congress
Safety and Efficacy of Early Everolimus in De Novo Orthotopic Liver Transplantation
Purpose: To study the safety and efficacy of immunosuppression with Everolimus (EVL) within the first month after orthotopic liver transplantation.Patients and methods: Recipients who had…2015 American Transplant Congress
Does Smoking Lead to Increased Rates of Acute Cellular Rejection in Liver Transplant Recipients?
Introduction: Prior studies of liver transplant recipients who smoke have shown associations between mortality and adverse outcomes. We investigated if smoking status at the time…2015 American Transplant Congress
De Novo Once-Daily Tacrolimus in Liver Transplantation: Long-Term Outcomes of a Single Center Cohort of 150 Patients
Purpose: To describe the long-term safety and efficacy profile of de novo once-daily tacrolimus (Tac QD) in orthotopic liver transplantation (OLT)Patients and methods: A retrospective…2015 American Transplant Congress
The Best Regimen With Rituximab for ABO-Incompatible Living Donor Liver Transplantation
Rituximab made a great progress on outcomes of ABO-incompatible living donor liver transplantation (ABO-I LDLT). Although Japanese multicenter study group published efficacy and safety of…
American Transplant Congress abstracts